Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1996 Nov;40(11):2529–2534. doi: 10.1128/aac.40.11.2529

In vivo efficacies of levofloxacin and ciprofloxacin in acute murine hematogenous pyelonephritis induced by methicillin-susceptible and-resistant Staphylococcus aureus strains.

M B Frosco 1, J L Melton 1, F P Stewart 1, B A Kulwich 1, L Licata 1, J F Barrett 1
PMCID: PMC163569  PMID: 8913458

Abstract

Levofloxacin, the active L-isomer of ofloxacin, has demonstrated strong activity against Staphylococcus aureus both in vitro and in vivo. In a murine model of hematogenous pyelonephritis, the in vivo efficacies of levofloxacin and ciprofloxacin were evaluated against two methicillin-susceptible and two methicillin-resistant S. aureus strains. All four isolates had virtually identical susceptibilities to levofloxacin and ciprofloxacin. Pyelonephritis was induced in carrageenan-primed mice by an intravenous injection of 0.5 ml of 10(7) CFU of methicillin-susceptible S. aureus isolates per ml or 10(8) CFU of methicillin-resistant S. aureus isolates per ml. At 1 h postinfection, the mice were treated orally with levofloxacin or ciprofloxacin once a day or twice a day (total daily dose of 20 to 160 mg/kg of body weight) for 4 days. Mice were euthanized 24 h after the final treatment, and the kidneys were excised and weighed. The kidneys were prepared for histological examination or were homogenized to determine the numbers of CFU per gram of tissue quantitatively. The reduction in the mean log10 number of CFU per gram as a function of total daily dose was recorded. A dose-response analysis showed that levofloxacin was superior to ciprofloxacin for all four isolates at any dose or regimen tested, independent of the methicillin susceptibility of the isolates. By using an inverse prediction technique, the equivalent effective doses of levofloxacin (once a day) were less than those of ciprofloxacin (twice a day) by 5.2 and 3.2 times, respectively, for methicillin-susceptible S. aureus 9039 and 3087. For methicillin-resistant S. aureus 667 and 2878, the equivalent effective doses of levofloxacin (once a day) were less than those of ciprofloxacin (twice a day) by 4.1 and 6.4 times, respectively. In a separate study, histological examination of all infected, untreated mice showed moderate to marked hematogenous pyelonephritis. Levofloxacin-treated mice (40 mg/kg once a day) showed no evidence of pyelonephritis in the kidneys, whereas the kidneys of mice treated with the same dose of ciprofloxacin showed only a reduction in the severity of the lesions. Treatment with ciprofloxacin (80 mg/kg twice a day) demonstrated a histology comparable to that of treatment with levofloxacin (40 mg/kg once a day). Levofloxacin (40 mg/kg once a day) reduced the log10 numbers of CFU per gram by 5 log10; however, ciprofloxacin (80 mg/kg twice a day) reduced the numbers of CFU per gram by only 3 log10. In the present murine model of pyelonephritis, levofloxacin was superior to ciprofloxacin in preventing pyelonephritis and eradicating S. aureus.

Full Text

The Full Text of this article is available as a PDF (1.1 MB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Davis R., Bryson H. M. Levofloxacin. A review of its antibacterial activity, pharmacokinetics and therapeutic efficacy. Drugs. 1994 Apr;47(4):677–700. doi: 10.2165/00003495-199447040-00008. [DOI] [PubMed] [Google Scholar]
  2. Dholakia N., Rolston K. V., Ho D. H., LeBlanc B., Bodey G. P. Susceptibilities of bacterial isolates from patients with cancer to levofloxacin and other quinolones. Antimicrob Agents Chemother. 1994 Apr;38(4):848–852. doi: 10.1128/aac.38.4.848. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Fernandes P. B., Chu D. T., Bower R. R., Jarvis K. P., Ramer N. R., Shipkowitz N. In vivo evaluation of A-56619 (difloxacin) and A-56620: new aryl-fluoroquinolones. Antimicrob Agents Chemother. 1986 Feb;29(2):201–208. doi: 10.1128/aac.29.2.201. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Fernandes P. B., Chu D. T., Swanson R. N., Ramer N. R., Hanson C. W., Bower R. R., Stamm J. M., Hardy D. J. A-61827 (A-60969), a new fluoronaphthyridine with activity against both aerobic and anaerobic bacteria. Antimicrob Agents Chemother. 1988 Jan;32(1):27–32. doi: 10.1128/aac.32.1.27. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Fernandes P. B., Swanson R. N. Correlation of in vitro activities of the fluoroquinolones to their in vivo efficacies. Drugs Exp Clin Res. 1988;14(6):375–378. [PubMed] [Google Scholar]
  6. Fowler E. F., Simpson J. G., Thomson A. W. Histological and ultrastructural changes following carrageenan injection in the mouse. J Pathol. 1980 Sep;132(1):63–79. doi: 10.1002/path.1711320107. [DOI] [PubMed] [Google Scholar]
  7. Fu K. P., Foleno B. D., Lafredo S. C., LoCoco J. M., Isaacson D. M. In vitro and in vivo antibacterial activities of FK037, a novel parenteral broad-spectrum cephalosporin. Antimicrob Agents Chemother. 1993 Feb;37(2):301–307. doi: 10.1128/aac.37.2.301. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Fu K. P., Lafredo S. C., Foleno B., Isaacson D. M., Barrett J. F., Tobia A. J., Rosenthale M. E. In vitro and in vivo antibacterial activities of levofloxacin (l-ofloxacin), an optically active ofloxacin. Antimicrob Agents Chemother. 1992 Apr;36(4):860–866. doi: 10.1128/aac.36.4.860. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Gargallo-Viola D., Esteve M., Llovera S., Roca X., Guinea J. In vitro and in vivo antibacterial activities of E-4497, a new 3-amine-3-methyl-azetidinyl tricyclic fluoroquinolone. Antimicrob Agents Chemother. 1991 Mar;35(3):442–447. doi: 10.1128/aac.35.3.442. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Goto S., Miyazaki S. New quinolones--in vivo antibacterial activity. Prog Drug Res. 1992;38:29–37. [PubMed] [Google Scholar]
  11. Hardy D. J., Swanson R. N., Hensey D. M., Ramer N. R., Bower R. R., Hanson C. W., Chu D. T., Fernandes P. B. Comparative antibacterial activities of temafloxacin hydrochloride (A-62254) and two reference fluoroquinolones. Antimicrob Agents Chemother. 1987 Nov;31(11):1768–1774. doi: 10.1128/aac.31.11.1768. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Ishii Y., Ohno A., Yamaguchi K. [In vitro antibacterial activities of broad spectrum quinolones against clinical bacterial isolates]. Jpn J Antibiot. 1994 Jan;47(1):22–28. [PubMed] [Google Scholar]
  13. Klesel N., Geweniger K. H., Koletzki P., Isert D., Limbert M., Markus A., Riess G., Schramm H., Iyer P. Chemotherapeutic activity of levofloxacin (HR 355, DR-3355) against systemic and localized infections in laboratory animals. J Antimicrob Chemother. 1995 Jun;35(6):805–819. doi: 10.1093/jac/35.6.805. [DOI] [PubMed] [Google Scholar]
  14. Yamane N., Jones R. N., Frei R., Hoban D. J., Pignatari A. C., Marco F. Levofloxacin in vitro activity: results from an international comparative study with ofloxacin and ciprofloxacin. J Chemother. 1994 Apr;6(2):83–91. doi: 10.1080/1120009x.1994.11741134. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES